Abstract
Background: A series of new symmetric disulfonamide and dicarbamate derivatives of 4,4ˈ- oxydianiline were designed and synthesized in a simple method. These compounds were characterized by IR, 1H, 13C-NMR, mass spectral data and elemental analysis.
Method: The compounds were screened for their in vitro antibacterial and antifungal activities against various pathogenic organisms. Among the title compounds 10f, 10a and 10h showed promising antibacterial activity and 10g, 10d and 10a showed good antifungal activity. Conclusion: The results also emphasized that the disulfonamide derivatives were better antibacterial agents than the corresponding dicarbamate derivatives.Keywords: 4, 4'-oxydianiline, disulfonamides, false metabolite, dicarbamates, sulphorhodamine-B (SRB) assay method, antibacterial activity, antifungal activity.
Graphical Abstract
Related Journals
Current Medicinal Chemistry
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Current HIV Research
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
Related Books
Frontiers in Clinical Drug Research: Anti-Infectives
Frontiers in Anti-Infective Drug Discovery
Coronaviruses
Moving From COVID-19 Mathematical Models to Vaccine Design: Theory, Practice and Experiences
COVID-19: Effects in Comorbidities and Special Populations
An Update on SARS-CoV-2: Damage-response Framework, Potential Therapeutic Avenues and the Impact of Nanotechnology on COVID-19 Therapy
Mitochondrial DNA and the Immuno-inflammatory Response: New Frontiers to Control Specific Microbial Diseases
An Epidemiological Update on COVID -19
Frontiers in Clinical Drug Research – Anti Allergy Agents
Frontiers in Clinical Drug Research: Anti-Infectives
36
1
1
1